--- title: "Harmony Biosciences Holdings (HRMY) news: lawsuit and settlement" url: "https://aibio.space/companies/harmony-biosciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "HRMY lawsuit and settlement news: Harmony Biosciences settles WAKIX patent suit with Lupin, generic entry set for 2030. Harmony Biosciences Holdings, Inc." --- HRMY Harmony Biosciences Holdings, Inc. NASDAQ · United States # Harmony Biosciences Holdings (HRMY) news HRMY lawsuit and settlement news Legal · 2025-06-05 ## [Harmony Biosciences settles WAKIX patent suit with Lupin, generic entry set for 2030](https://aibio.space/news/harmony-biosciences-settles-wakix-patent-suit-lupin-generic-entry-set/) Lupin Limited gets a license to launch a generic WAKIX no earlier than January 2030, or July 2030 with pediatric exclusivity, and the Delaware case will be dismissed. ## Latest Harmony Biosciences Holdings news We have not published a story on Harmony Biosciences Holdings yet. When there is news, it will appear here. ## Harmony Biosciences Holdings at a glance - **Ticker**: HRMY - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $667.8 million ### Related companies - [Pulmatrix](https://aibio.space/companies/pulmatrix/) NASDAQ: PULM - [Connect Biopharma Holdings](https://aibio.space/companies/connect-biopharma/) NASDAQ: CNTB - [Protagenic Therapeutics](https://aibio.space/companies/protagenic-therapeutics/) OTC: PTIX - [Cumberland Pharmaceuticals](https://aibio.space/companies/cumberland-pharmaceuticals/) NASDAQ: CPIX - [Werewolf Therapeutics](https://aibio.space/companies/werewolf-therapeutics/) NASDAQ: HOWL - [Sarepta Therapeutics](https://aibio.space/companies/sarepta-therapeutics/) NASDAQ: SRPT - [Structure Therapeutics](https://aibio.space/companies/structure-therapeutics/) NASDAQ: GPCR - [Kairos Pharma](https://aibio.space/companies/kairos-pharma/) AMEX: KAPA ### Also on NASDAQ - [Jin Medical International](https://aibio.space/companies/jin-medical-international/) ZJYL - [OmniAb](https://aibio.space/companies/omniab/) OABI - [enVVeno Medical](https://aibio.space/companies/envveno-medical/) NVNO - [Eloxx Pharmaceuticals](https://aibio.space/companies/eloxx-pharmaceuticals/) ELOX - [Dermata Therapeutics](https://aibio.space/companies/dermata-therapeutics/) DRMA - [Nyxoah SA](https://aibio.space/companies/nyxoah/) NYXH ## What Harmony Biosciences Holdings does Harmony Biosciences Holdings, Inc. is a neuroscience company focused on rare neurological diseases across sleep/wake, rare epilepsy and neurobehavioral conditions. Its lead product, WAKIX (pitolisant), is described as a first-in-class molecule that enhances histamine signaling in the brain by binding to H3 receptors. WAKIX is approved for excessive daytime sleepiness and cataplexy in adults with narcolepsy, with later approvals for pediatric patients six years and older. The company says it is the only FDA-approved narcolepsy treatment that is not scheduled as a controlled substance by the U.S. Drug Enforcement Administration. Net product revenue related to WAKIX was $868.5 million for the year ended December 31, 2025. Harmony has late-stage programs exploring pitolisant in idiopathic hypersomnia, Prader-Willi syndrome and myotonic dystrophy type 1. Its rare epilepsy programs include EPX-100, in two Phase 3 registrational trials for Dravet Syndrome and Lennox-Gastaut Syndrome, and EPX-200, in the pre-IND phase for developmental and epileptic encephalopathies. The company also holds a preclinical orexin 2 receptor agonist, BP1.15205, sublicensed from Bioprojet, and has a research collaboration with the related party CiRC Biosciences, Inc. on discovery-stage candidates. | Product or program | What it is | Stage | |---|---|---| | WAKIX (pitolisant) | First-in-class H3 receptor antagonist/inverse agonist for narcolepsy | approved by FDA | | Pitolisant GR | Gastro-resistant next-generation pitolisant formulation | clinical development | | Pitolisant HD | High-dose next-generation pitolisant formulation | clinical development | | EPX-100 | Serotonin (5HT-2) receptor agonist for rare epilepsy | Phase 3 | | EPX-200 | Selective 5HT-2C agonist for developmental and epileptic encephalopathies | pre-IND | | BP1.15205 | Orexin 2 receptor agonist for narcolepsy | preclinical | Summarised from the company's [10-K filed Feb 24, 2026](https://www.sec.gov/Archives/edgar/data/1802665/000110465926018859/hrmy-20251231x10k.htm). ## Harmony Biosciences Holdings annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$868.5 million](https://www.sec.gov/Archives/edgar/data/1802665/000110465926018859/) | [$714.7 million](https://www.sec.gov/Archives/edgar/data/1802665/000110465926018859/) | | Research and development | [$189.6 million](https://www.sec.gov/Archives/edgar/data/1802665/000110465926018859/) | [$145.8 million](https://www.sec.gov/Archives/edgar/data/1802665/000110465926018859/) | | Net income (loss) | [$158.7 million](https://www.sec.gov/Archives/edgar/data/1802665/000110465926018859/) | [$145.5 million](https://www.sec.gov/Archives/edgar/data/1802665/000110465926018859/) | | Cash from operations | [$348.2 million](https://www.sec.gov/Archives/edgar/data/1802665/000110465926018859/) | [$219.8 million](https://www.sec.gov/Archives/edgar/data/1802665/000110465926018859/) | | Cash and equivalents | [$752.5 million](https://www.sec.gov/Archives/edgar/data/1802665/000110465926090090/) | [$453.0 million](https://www.sec.gov/Archives/edgar/data/1802665/000110465926018859/) | | Short-term investments | [$22.8 million](https://www.sec.gov/Archives/edgar/data/1802665/000110465926090090/) | [$14.2 million](https://www.sec.gov/Archives/edgar/data/1802665/000110465926018859/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $549.8 million, plus short-term investments of $118.0 million, $667.8 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Harmony Biosciences Holdings Is Harmony Biosciences Holdings involved in a lawsuit? Our latest story on this, dated Jun 5, 2025: "Harmony Biosciences settles WAKIX patent suit with Lupin, generic entry set for 2030". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/harmony-biosciences-settles-wakix-patent-suit-lupin-generic-entry-set/). Has Harmony Biosciences Holdings settled a lawsuit? Our latest story on this, dated Jun 5, 2025: "Harmony Biosciences settles WAKIX patent suit with Lupin, generic entry set for 2030". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/harmony-biosciences-settles-wakix-patent-suit-lupin-generic-entry-set/). What is the ticker symbol of Harmony Biosciences Holdings? Harmony Biosciences Holdings, Inc. trades under the ticker HRMY on NASDAQ. Where is Harmony Biosciences Holdings listed? Harmony Biosciences Holdings, Inc. is listed on NASDAQ. Our directory also records these other listings: BMV:HRMY. What is the SEC CIK of Harmony Biosciences Holdings? The SEC Central Index Key (CIK) for Harmony Biosciences Holdings, Inc. is 1802665. Its filings are on SEC EDGAR. How many shares does Harmony Biosciences Holdings have outstanding? 58,236,393 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-04. Which country or territory is Harmony Biosciences Holdings listed under? Our directory records Harmony Biosciences Holdings, Inc. under United States. What does Harmony Biosciences Holdings do? Our directory classifies Harmony Biosciences Holdings, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Harmony Biosciences Holdings? The ISIN recorded for Harmony Biosciences Holdings, Inc. is US4131971040. Does aibio.space cover Harmony Biosciences Holdings? aibio.space lists Harmony Biosciences Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Harmony Biosciences Holdings incorporated? SEC records list its state or country of incorporation as DE. What does Harmony Biosciences Holdings develop? Harmony Biosciences Holdings, Inc. is a neuroscience company focused on rare neurological diseases across sleep/wake, rare epilepsy and neurobehavioral conditions. Its lead product, WAKIX (pitolisant), is described as a first-in-class molecule that enhances histamine signaling in the brain by binding to H3 receptors. What is WAKIX (pitolisant) from Harmony Biosciences Holdings? WAKIX (pitolisant): First-in-class H3 receptor antagonist/inverse agonist for narcolepsy Stage: approved by FDA. What is Pitolisant GR from Harmony Biosciences Holdings? Pitolisant GR: Gastro-resistant next-generation pitolisant formulation Stage: clinical development. What was Harmony Biosciences Holdings's revenue last year? $868.5 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. ## Investor discussion: Harmony Biosciences Holdings Members talk about Harmony Biosciences Holdings (HRMY). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Harmony Biosciences Holdings, newest first. Each line links the filing it comes from. 1. 2025-02-25 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/1802665/000110465925016930/tm257349-1_s3asr.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:HRMY on TradingView](https://www.tradingview.com/symbols/NASDAQ-HRMY/). ## SEC filings and registration - **SEC name**: Harmony Biosciences Holdings, Inc. - **CIK**: 1802665 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: HRMY (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 630 W GERMANTOWN PIKE, PLYMOUTH MEETING, PA, 19462 - **Phone**: (484) 539-9800 - **Shares outstanding**: 58,236,393 as of 2026-07-31 (10-Q filed 2026-08-04) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1802665/000110465926115282/hrmy-20261012x8k.htm) filed 2026-10-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/1802665/000110465926090090/hrmy-20260630x10q.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1802665/000110465926090086/hrmy-20260804x8k.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1802665/000110465926084095/hrmy-20260716x8k.htm) filed 2026-07-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1802665/000110465926061237/hrmy-20260514x8k.htm) filed 2026-05-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1802665/000110465926056786/hrmy-20260507x8k.htm) filed 2026-05-07 - [10-Q](https://www.sec.gov/Archives/edgar/data/1802665/000110465926056720/hrmy-20260331x10q.htm) filed 2026-05-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1802665/000110465926042886/hrmy-20260414x8k.htm) filed 2026-04-14 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001802665), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Harmony Biosciences Holdings, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker HRMY, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Harmony Biosciences Holdings, Inc. - **Ticker**: HRMY - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US4131971040 - **Other listed symbols**: BMV:HRMY - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-HRMY/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/harmony-biosciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Harmony Biosciences Holdings (HRMY) news: lawsuit and settlement", 2026-10-31, https://aibio.space/companies/harmony-biosciences/